公司资料
Vaxcyte 股价、新闻与催化剂
- 股票代码:
- PCVX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
60.22 USD (+3.70%)
收盘价
最后更新: 2026年8月17日
6.85B USD
市值
股价为何变动
As of Aug 17, 2026, PCVX closed up 3.70% at $60.22. No new same-company headline was identified in the current news window.
公司概览
Carrier-Sparing Vaccine Platform
Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses.
Adult VAX-31 Program
VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The OPUS program compares its immune responses with currently available pneumococcal vaccines and evaluates coadministration and safety.
Infant VAX-31 Program
A Phase 2 dose-finding study is evaluating VAX-31 as part of the primary infant immunization series and a booster dose.
VAX-A1
VAX-A1 is a preclinical vaccine designed to protect against disease caused by Group A *Streptococcus* and is preparing for initial testing in adults.
Manufacturing Infrastructure
Vaxcyte and Lonza have completed construction of dedicated large-scale manufacturing capacity intended to support future global supply of the company's pneumococcal vaccines.
未来催化剂
- Initiation of a Phase 1 adult study of VAX-A1 around mid-2026.
- Topline Phase 3 OPUS-1 data for VAX-31 in the fourth quarter of 2026.
- Phase 3 OPUS-2 and OPUS-3 results in the first half of 2027.
- Infant Phase 2 primary-series and booster data by the end of the first half of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。